Using CRT exposure and HMGB1 release as surrogate markers for drug-induced tumor cell immunogenicity, we found that OxP treatment indeed induced immunogenic effects on CT26-FL3 cells (Supplementary Fig. 2a, b). Here, CALR is linked to neoplasm.